◆英語タイトル:Vistin Pharma AS (VISTIN) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013400
◆発行会社(調査会社):
GlobalData
◆発行日:2017年11月28日
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ノルウェー
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
※
販売価格オプションの説明はこちらで、
ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※
GlobalData社の概要はこちらでご確認いただけます。
【レポートの概要】
Summary
Vistin Pharma AS (Vistin), a subsidiary of Vistin Pharma ASA is a healthcare company that produces and supplies solid dosage forms and active pharmaceutical ingredients. The company’s products include metformin, an API for the treatment of diabetes II; opioids, an analgesics and antitussive; and pholcodine, an antitussive. It provides contract manufacturing for granulate and solid dosage forms and offers customer service, logistics and technical services. Vistin offers plain generic and branded generic metformin tablets, and branded and patented combinations products. The company offers its services to international pharmaceutical companies. It operates through a network of distributors and agents across Europe, Asia, Africa and America. The company’s manufacturing facilities are located in Sannidal and Kragero, Norway. Vistin is headquartered in Oslo, Norway.
Vistin Pharma AS (VISTIN) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.
Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.
Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Vistin Pharma AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deal Details 9
Equity Offering 9
Vistin Pharma Raises USD20 Million in Rights Offering of Shares 9
Asset Transactions 10
TPI Enterprises Acquires Opioids and CMO Business from Vistin Pharma 10
Acquisition 11
Geveran Trading Divests 5.17% Stake in Vistin Pharma 11
Vistin Pharma AS – Key Competitors 12
Vistin Pharma AS – Key Employees 13
Vistin Pharma AS – Locations And Subsidiaries 14
Head Office 14
Recent Developments 15
Financial Announcements 15
Oct 27, 2017: Vistin Pharma: Third quarter 2017 results – strong growth, capacity expansion on track 15
Apr 26, 2017: Vistin Pharma: First quarter 2017 results 16
Feb 28, 2017: Vistin Pharma: Fourth quarter and preliminary 2016 results 17
Oct 31, 2016: Vistin Pharma third quarter 2016: Investing in future growth 18
Aug 30, 2016: Vistin Pharma: Solid Second Quarter Driven by all-time High Metformin Revenue 19
Apr 28, 2016: Vistin Pharma : Strong First Quarter 2016 And Bright Outlook 20
Feb 23, 2016: Vistin Pharma: Solid Fourth Quarter Results and Positive Market Outlook 21
Other Significant Developments 22
Aug 31, 2017: Vistin Pharma Second quarter 2017 results – continuing strong demand for metformin 22
Dec 05, 2016: Vistin Pharma announces cost savings plan of NOK 20-30 million on an annualised basis 23
Nov 18, 2016: Vistin Pharma’s metformin production temporarily halted due to an unscheduled maintenance stop 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25
List of Tables
Vistin Pharma AS, Pharmaceuticals & Healthcare, Key Facts, 2016 2
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 2
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Vistin Pharma AS, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Vistin Pharma AS, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 8
Vistin Pharma Raises USD20 Million in Rights Offering of Shares 9
TPI Enterprises Acquires Opioids and CMO Business from Vistin Pharma 10
Geveran Trading Divests 5.17% Stake in Vistin Pharma 11
Vistin Pharma AS, Key Competitors 12
Vistin Pharma AS, Key Employees 13